Truist Financial Begins Coverage on Perspective Therapeutics (NYSE:CATX)

Truist Financial initiated coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note released on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $21.00 price target on the stock.

Other analysts have also issued reports about the stock. Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating for the company in a research report on Friday, August 16th. Oppenheimer reduced their price objective on Perspective Therapeutics from $19.00 to $17.00 and set an outperform rating for the company in a research note on Tuesday, August 13th. Bank of America began coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a buy rating and a $24.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $20.00.

Perspective Therapeutics Trading Up 2.4 %

CATX opened at $12.55 on Wednesday. The company’s 50-day moving average is $13.81. Perspective Therapeutics has a 52-week low of $2.20 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million for the quarter. As a group, analysts expect that Perspective Therapeutics will post -0.86 EPS for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CATX. WealthPLAN Partners LLC bought a new position in Perspective Therapeutics during the 2nd quarter worth about $1,695,000. Bank of New York Mellon Corp grew its stake in Perspective Therapeutics by 214.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after buying an additional 93,548 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of Perspective Therapeutics during the second quarter valued at about $841,000. Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics during the 2nd quarter valued at approximately $3,951,000. Finally, Rhumbline Advisers purchased a new position in Perspective Therapeutics in the 2nd quarter worth $630,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.